The BNT162 program is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities. The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world. BioNTech is the market authorization holder worldwide and will hold all trademarks for the potential product. Both collaborators are committed to developing these novel vaccines with pre-clinical and clinical data at the forefront of all their decision-making. 独家技术是德国BioNTech提供的，trademarks也是人家的， Pfizer没有产权的。 Pfizer不过是辅助作用。 BioNTech可以选择和任何一家药厂合作搞clinical trials和疫苗生产，Pfizer有幸被选到。 还有FDA的批准只是针对美国市场。 这个疫苗要在欧洲和其他国家上架要得到当地政府的批准， 和FDA没关系。BioNTech在德国有自己的工厂可以生产疫苗， 又刚刚从瑞士药厂手里买下另外一个工厂扩大生产。 这个新厂生产的疫苗将专供欧盟和中国市场。Pfizer生产的疫苗主要是提供美国市场。
on SEC.gov, you understand co-develop? Pfizer COVID-19 Collaboration On April 9, 2020, we announced that we and Pfizer had entered into a collaboration agreement to co-develop our potential first-in-class COVID-19 mRNA vaccine program, BNT162, aimed at preventing COVID-19. Under the terms of the agreement, Pfizer agreed to pay us $185 million in upfront payments, including an equity investment of €103.9 million ($113 million, translated using the exchange rate then in effect as published by the German Central Bank (Deutsche Bundesbank)), which was received in late April 2020, and a cash payment of €65.5 million ($72 million, translated using the exchange rate then in effect as published by the German Central Bank (Deutsche Bundesbank)), which was received in May 2020. The issuance of 2,377,446 ordinary shares with the nominal amount of €2,377,446 was registered within the commercial register (Handelsregister) as of May 5, 2020. We are eligible to receive future milestone payments of up to $563 million for potential aggregate consideration of $748 million. Pfizer and we will share development costs equally. Initially, Pfizer will fund 100% of the development costs, and we will repay Pfizer our 50% share of these costs if success-based milestones are reached, or with proceeds generated from the commercialization of the vaccine, if approved. If the vaccine program is not successful or does not generate sufficient proceeds, we will not be required to pay back our 50% share of the development costs incurred. We and Pfizer are jointly conducting clinical trials for four COVID-19 vaccine candidate variants initially in the United States and Europe across multiple sites.
https://www.bloomberg.com/news/articles/2020-11-09/pfizer-vaccine-s-funding-came-from-berlin-not-washington
side track一下，biontech ceo是turkey的移民。
给个100m的预采购协议，投资人会更愿意承担投资风险，这是合作和很大信心支持呀
我觉得在疫苗没开发出来就无偿投资的要承担更大风险，你觉得呢？
那要看采购合同的规定。 德国的研发经费一直都有的，是政府每年预算里的支出，所以德国政府是没有额外的风险。
嗯 对啊 钱都给Moderna那个忙着炒股的公司了呀 Pfizer人家不收这个钱 嘿嘿
但是某些人一定要给领袖唱赞歌 这可打了大国沙文主义的脸 新孤立主意的脸了呀
不是黑川了，这是在黑美国啊，为了将来方便盗窃知识产权吧，先把美国从可能成功疫苗上摘出去。虽然美国肯定不会搞什么疫苗外交，毕竟德国比较圣母。
The BNT162 program is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities. The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world. BioNTech is the market authorization holder worldwide and will hold all trademarks for the potential product. Both collaborators are committed to developing these novel vaccines with pre-clinical and clinical data at the forefront of all their decision-making.
独家技术是德国BioNTech提供的，trademarks也是人家的， Pfizer没有产权的。 Pfizer不过是辅助作用。 BioNTech可以选择和任何一家药厂合作搞clinical trials和疫苗生产，Pfizer有幸被选到。
还有FDA的批准只是针对美国市场。 这个疫苗要在欧洲和其他国家上架要得到当地政府的批准， 和FDA没关系。BioNTech在德国有自己的工厂可以生产疫苗， 又刚刚从瑞士药厂手里买下另外一个工厂扩大生产。 这个新厂生产的疫苗将专供欧盟和中国市场。Pfizer生产的疫苗主要是提供美国市场。
Pfizer COVID-19 Collaboration On April 9, 2020, we announced that we and Pfizer had entered into a collaboration agreement to co-develop our potential first-in-class COVID-19 mRNA vaccine program, BNT162, aimed at preventing COVID-19. Under the terms of the agreement, Pfizer agreed to pay us $185 million in upfront payments, including an equity investment of €103.9 million ($113 million, translated using the exchange rate then in effect as published by the German Central Bank (Deutsche Bundesbank)), which was received in late April 2020, and a cash payment of €65.5 million ($72 million, translated using the exchange rate then in effect as published by the German Central Bank (Deutsche Bundesbank)), which was received in May 2020. The issuance of 2,377,446 ordinary shares with the nominal amount of €2,377,446 was registered within the commercial register (Handelsregister) as of May 5, 2020. We are eligible to receive future milestone payments of up to $563 million for potential aggregate consideration of $748 million. Pfizer and we will share development costs equally. Initially, Pfizer will fund 100% of the development costs, and we will repay Pfizer our 50% share of these costs if success-based milestones are reached, or with proceeds generated from the commercialization of the vaccine, if approved. If the vaccine program is not successful or does not generate sufficient proceeds, we will not be required to pay back our 50% share of the development costs incurred. We and Pfizer are jointly conducting clinical trials for four COVID-19 vaccine candidate variants initially in the United States and Europe across multiple sites.